News und Analysen
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Humana to Partner with Two National Durable Medical Equipment Organizations
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it has reached agreement with two national organizations to provide Durable Medical Equipment (DME) services to
Charles River Laboratories Announces First-Quarter 2023 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Sensorion Will Present Two Posters At The American Society Of Cell And Gene Therapy (ASGCT) 26th Annual Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its participation in
Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM
Chemed Corporation to Present at the 2023 RBC Global Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at approximately 2:35 p.m. (ET)
Transgene provides business update and Q1 2023 financial position
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update, including
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of a new integrated
The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been
EQS-News: Formycon Announces Participation in International Investor Conferences in Q2/2023
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Convatec Group PLC: Scrip Dividend - Total Issued Shares
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced data from the kidney biopsy sub-study of the AURORA clinical trial program (AURORA 1 and AURORA 2 Extension
Premier, Inc. Evaluating Strategic Alternatives
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors is evaluating potential strategic alternatives to enhance value
IMV Receives NASDAQ Delisting Notice
IMV Inc. (the “Company” or “IMV”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat
Xencor Reports First Quarter 2023 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Annual General Meeting of Kuros Biosciences approves all resolutions
Owens & Minor to Present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023
Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services, announced today that Ed